Evidence map›Paper›PMID 38494480›Full record

ArticleEuropean journal of medical research2024

Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.

Mengna Zhao, Yang Gao, Junyuan Yang, Hao He, Min Su, Shimeng Wan, Xiaoye Feng, Hua Wang, Hongbing Cai

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mengna Zhao *Department of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Yang Gao *Department of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Junyuan Yang *Department of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Hao HeDepartment of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Min SuDepartment of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Shimeng WanDepartment of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Xiaoye FengDepartment of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Hua Wang *Department of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China.
Hongbing Cai *Department of Gynecological Oncology, Hubei Clinical Cancer Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, No. 169 East Lake Road, Wuhan, 430071, People's Republic of China. chb2105@163.com.
Wuhan University · CNZhongnan Hospital of Wuhan University · CNHubei Cancer Hospital · CN

Funding

Hubei Province health and family planning scientific research project WJ2023M067National Natural Science Fund 8197103302
6 · The paper itself

Abstract

objectiveWe aimed to evaluate the ability of Adult Comorbidity Evaluation 27 (ACE-27) to predict perioperative outcomes and survival in elderly women with advanced epithelial ovarian cancer (AEOC) undergoing cytoreductive surgery.

methodsWe collected patients with AEOC in our hospital between January 1, 2012 and January 1, 2021. Patients younger than 65 years old or those with non-epithelial ovarian cancer were excluded. ACE-27 was applied retrospectively to assess comorbidities in the selected patients, who were then classified into two groups based on their ACE-27 scores: low ACE-27 score group (none to mild) and high ACE-27 score group (moderate to severe).

resultsA total of 222 elderly women with AEOC were included, of whom 164 patients accepted debulking surgery. Among those who have undergone surgery, Clavien-Dindo grade III + perioperative complications or unintended intensive care unit (ICU) admission occurred more often in patients of high ACE-27 score group, with statistically significant difference (odds ratio [OR]: 4.21, 95% confidence interval [CI], 1.28-14.35, p = 0.018). Further stratified analyses by age, BMI, FIGO stage and pathology also prove that OS of patients graded severe was shorter than patients graded none to moderate in cohort of age < 70, BMI < 25 kg/m

conclusionsOur findings demonstrate the ability of ACE-27 to predict grade III + perioperative complications or unintended ICU admission and survival in elderly patients with AEOC. This highlights the possibility for ACE-27 to play an instrumental role in identifying AEOC patients who are more susceptible to adverse surgical outcomes and have a poor survival rate and assisting in decisions regarding treatment.

Indexed as

Ovarian NeoplasmsAdultAgedCarcinoma, Ovarian EpithelialComorbidityCytoreduction Surgical ProceduresFemaleHumansRetrospective StudiesTreatment OutcomeACE-27ComorbidityElderlyOvarian cancerSurgery

Identifiers

PMID38494480
PMCPMC10946157
OpenAlexW4392895257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.